
|Articles|February 1, 2004
No formulary should restrict itself to one SSRI for treatment of depression
Experts say SSRIs tend to have similar efficacy but different side effect profiles, and patients who don't respond to one might respond to another
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Myqorzo is now available for rare heart condition at a $108,400 annual price
2
PBM reform. It has finally happened
3
Melanoma diagnoses projected to rise in 2026
4
ACHP announces new funding to elevate patient voices in diabetes research
5























